AZD-3514

Investigational

Details

Stereochemistry	ACHIRAL
Molecular Formula	C25H32F3N7O2
Molecular Weight	519.5625
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(=O)N1CCN(CCOC2=CC=C(C=C2)C3CCN(CC3)C4=NN5C(CC4)=NN=C5C(F)(F)F)CC1

InChI

InChIKey=JMEYDSHPKCSIJC-UHFFFAOYSA-N

InChI=1S/C25H32F3N7O2/c1-18(36)33-14-12-32(13-15-33)16-17-37-21-4-2-19(3-5-21)20-8-10-34(11-9-20)23-7-6-22-29-30-24(25(26,27)28)35(22)31-23/h2-5,20H,6-17H2,1H3

HIDE SMILES / InChI

Molecular Formula	C25H32F3N7O2
Molecular Weight	519.5625
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23861347 | https://www.ncbi.nlm.nih.gov/pubmed/25920479

AZD-3514 is a down-regulator of androgen receptors. The drug was synthesized by AstraZeneca for the treatment of castrate-resistant prostate cancer and even reached phase I, however, its development was terminated.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Androgen receptor 42 Target ID: P10275 Gene ID: 367.0 Gene Symbol: AR Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/23466225	Modulator 828		5.75 null [pIC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Castrate-resistant prostate cancer 20 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25920479	Primary		Phase I 428	Unknown Approved Use Unknown

C_max

Value	Dose	Co-administered	Analyte	Population
9750 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25920479	1000 mg 1 times / day steady-state, oral dose: 1000 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		AZD-3514 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
36890 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25920479	1000 mg 1 times / day steady-state, oral dose: 1000 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		AZD-3514 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

Sourcing

Vendor/Aggregator	ID	URL
1PlusChem LLC	1P009CPV	https://www.1pchem.com/search?query=1P009CPV
AK Scientific	2239AH	https://aksci.com/item_detail.php?cat=2239AH
AOBIOUS INC	AOB87377	http://aobious.com/aobious/search?search_query=AOB87377
Angene	AGN-PC-0WACGO	http://www.angenechemical.com/productshow/AGN-PC-0WACGO.html
ApexBio Technology	A1372	https://www.apexbt.com/catalogsearch/result/?q=A1372
BLD Pharm	BD559115	http://www.bldpharm.com/search/Search.html?keyword=BD559115
Chem Scene	CS-1443	http://www.chemscene.com/goproductList/searchProductList?productObj=CS-1443
ChemShuttle	111852	https://www.chemshuttle.com/catalogsearch/result/?q=111852
Debye Scientific	DA-35308	https://www.debyesci.com/index.php?id=product&ext[cno]=DA-35308
Excenen	EX-A1806	http://www.excenen.com/searchresultlist.php?id=EX-A1806
Matrix Scientific	147200	http://www.matrixscientific.com/147200.html
MedChem Express	HY-16079	https://www.medchemexpress.com/search.html?q=HY-16079&ft=&fa=&fp=
MolPort	MolPort-035-395-802	https://www.molport.com/shop/molecule-link/MolPort-035-395-802
Molnova	M10970	https://www.molnova.com/en/serch-list.html?keywords=M10970
MuseChem	I000960	https://www.musechem.com/product/I000960.html
Selleck Chemicals	S7040	http://www.selleckchem.com/search.html?searchDTO.searchParam=S7040
ShangHai Biochempartner	BCP000930	http://www.biochempartner.com/search_BCP000930
ShangHai Biochempartner	BCP07896	http://www.biochempartner.com/search_BCP07896
TargetMol	T6400	https://www.targetmol.com/search?keyword=T6400
eMolecules	49383439	https://orderbb.emolecules.com/search/#?query=49383439
eNovation Chemicals	D372357	https://www.enovationchem.com/Products.asp?SEARCHTEXT=D372357&searchbtn.x=0&searchbtn.y=0
mcule	MCULE-7923912870	https://mcule.com/MCULE-7923912870/

PubMed

Title	Date	PubMed
Discovery of AZD3514, a small-molecule androgen receptor downregulator for treatment of advanced prostate cancer.	2013 Apr 1	23466225

Patents

Sample Use Guides

In Vivo Use Guide

Patients were treated with escalating doses of AZD-3514, where starting doses were 100, 250 and 1000 mg/day.

Route of Administration: Oral

In Vitro Use Guide

LNCaP cells were treated with AZD-3514 for 24 hours at doses 0.4, 1.1, 3.3, 10, 30 uM. The drug inhibited DHT driven proliferation of LNCaP cells in a dose-dependent manner. The DHT driven proliferation of LAPC4 cells was also inhibited by 10 uM of AZD-3514.

Substance Class	Chemical Created by `admin` on `Sat Dec 16 01:42:06 GMT 2023` Edited by `admin` on `Sat Dec 16 01:42:06 GMT 2023`
Record UNII	127DSS8X7J
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

AZD-3514

Code

English

CS-1443

Code

English

ETHANONE, 1-(4-(2-(4-(1-(7,8-DIHYDRO-3-(TRIFLUOROMETHYL)-1,2,4-TRIAZOLO(4,3-B)PYRIDAZIN-6-YL)-4-PIPERIDINYL)PHENOXY)ETHYL)-1-PIPERAZINYL)-

Systematic Name

English

AZD 3514 [WHO-DD]

Common Name

English

Code System Code Type Description

SMS_ID

100000177726